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glutide than with sitagliptin based on data from a recently published 52-week
clinical trial.
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OBJECTIVES: To evaluate the cost effectiveness of pharmacist intervention (the
enhanced care group-ECG) relative to primary care physicians only (control group)
in improving cardiovascular (CVD) outcomes among patients with Type 2 diabetes
mellitus (T2DM). METHODS: Data were collected from medical charts at Kaiser
Permanente (KP) clinics. Patients in the ECG were matched 1:1 to patients in the
control group based on age, gender, HbA1C, and Charlson comorbidity score. The
UKPDS risk engine was used to estimate the 10-year CVD risk. A Markov state-
transitionmodel was developed to simulate the difference in CVD risk between the
two hypothetical cohorts of ECG and control group. The primary outcome was the
incremental cost and effectivenessmeasured by life years and per quality-adjusted
life year (QALY) gained. Sensitivity analysis(SA) was conducted to examine the
robustness of the results. RESULTS: The base case model suggests that the ECG
dominated the control group with lower treatment cost ($35,740 vs. $44,528) per
patient and more life years (8.9 vs.8.1) and QALY (5.51 vs. 5.02) over the 10-year
period. Within the reasonable range of variability of all parameters, however, the
multiple one-way SA revealed that the relative value of ECG depends on the time
horizon adopted by the payers. The probabilistic sensitivity analysis suggests that
when adopting a longer time horizon such as 5 or more years in management, the
ECG has a far higher chance of being chosen as a cost-effective strategy regardless
of the level of willingness to pay. When the time horizon was shortened, however,
the likelihood for the ECG being cost- effective decreased. CONCLUSIONS: Adding
pharmacists to the health care management team for diabetic patients can be a
cost-effective strategy in terms of the improvements in the cardiovascular out-
come achieved over the long term.
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OBJECTIVES: 1) To identify key features of cost-effectiveness analyses (CEAs) of
type 2 diabetes mellitus (T2DM) of the United States (US) population; 2) to assess
the quality of T2DM CEAs; and 3) to identify the predictors of quality. METHODS:
We searched PubMed for several MeSH terms with English language restriction,
through August 2011. The quality of eligible studies was evaluated using the Qual-
ity of Health Economic Evaluation (QHES) instrument. Multiple linear regression
analysis was conducted for the predictors of quality (overall QHES score) and inde-
pendent variables being features of the T2DMCEA literature.RESULTS:A total of 38
full-text articles met inclusion criteria of which: Forty-six percent were pharma-
ceutical companies funded/sponsored, 82% were conducted from healthcare pay-
ers perspective, 77%were published in clinical-focused journals, 85% used quality-
adjusted life-years (QALYs), 79% used published literature as the data source, 28%
used the Center for Outcomes Research diabetes model, 51% were classified as
disease treatment/management, and 64% used more than one-way sensitivity
analysis. Overall, mean quality score using QHES was 73.211.5 and only 51% of
studies scored75 (high-quality). Many studies (69%) failed to describe the analysis
perspective and/or reasons for its selection; whereas, most of the studies (95%)
used valid and reliable health outcomes scales/measures. Multiple linear regres-
sion found the following significant variables (p0.05): journal impact factor
(11.2, CI7.4-14.0), studies using QALY (34.9, CI11.2-48.1), and published
after year 2000 (35.8, CI13.9-48.6). CONCLUSIONS: All studies funded/spon-
sored by a pharmaceutical company concluded the product of that company to be
cost-effective; thismay be indicative of publication bias and/or design bias. Several
studies failed to follow the societal perspective recommendations of the US Panel
on Cost-effectiveness in Health and Medicine, possibly because of preferences of
the funding agency or researcher’s interests. Decisions based on these studies
should consider quality and other key features of the later.
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OBJECTIVES: Pharmacist-provided medication therapy management (MTM) has
been reported to improve patient outcomes in a variety of settings and patient
populations. Yet, little is known about the long-term economic and clinical out-
comes of MTM. Here, we sought to estimate the incremental, lifetime cost-effec-
tiveness of MTM in type 2 diabetes, over usual dispensing care, from a health
payer perspective. METHODS: We constructed a decision-analytic Markov model
with 10 diabetes disease states. A hypothetical cohort of 40-year-old patients were
followed for the rest of their life expectancy (31 years). Transition probabilities
were derived from the validated CDC-RTI diabetes model. Costs (in 2010 dollars)
associated with each disease state were derived from the ADA’s 2007 report on
diabetes costs. In the base case, MTMwas assumed to increase annual, per-patient
direct medical costs by 1.7%, which is a median of values retrieved from the liter-
ature. Glycemic levels reported under MTMwere used to model the corresponding
effects on the risks for microvascular complications via an exponential parametric
form (Eastman 1997). Risk reduction for coronary heart disease under MTM was
taken from the Fremantle Diabetes Trial. The primary outcome of the model is the
incremental cost per quality-adjusted life-years (QALYs) gained. Future costs and
QALYs were discounted at 3% per annum. Sensitivity analyses were undertaken to
assess model robustness and uncertainties. RESULTS: Over usual care, MTMwas
estimated to result in an additional 0.44 QALYs, and in lifetime cost savings of
approximately $20,000 per patient. MTM appeared to improve survival by 4%. Our
estimates are robust to plausible variations in key parameters, and are most sen-
sitive to the probability of nephropathy, and to the effect of MTM on costs.
CONCLUSIONS: Our results suggest that MTM dominates usual care. The increase
in direct medical costs associated with MTM appears to be offset by large cost
savings due to reduction in diabetes-related morbidity and mortality.
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OBJECTIVES: To determine the cost-utility of pregabalin (PRE) vs. duloxetine (DUL)
over a 6 month time horizon from the perspective of US third-party payers using a
decision tree analysis.METHODS: Literature searches identified clinical trials and
real-world studies reporting the efficacy, tolerability, safety, adherence, opioid us-
age, and healthcare utilization and costs of PRE and DUL. The proportions of pa-
tients reported in the included studies were used to determine probabilities in the
decision tree model. Average wholesale price was used to determine the costs of
medications. The costs associated with healthcare utilization were determined
from observational studies and all costs were adjusted to 2011 US dollars. Utility
values formoderate to severe andmild painwere determined fromEuroQoL scores.
The overall utility values were determined by multiplying the utility values by the
disutility values associatedwith adverse events. The base-casemodel included the
FDA approved doses of PRE (300 mg/day) and DUL (60 mg/day) while “real-world”
sensitivity analyses explored the effects over a range of doses (PRE 75-600 mg/day,
DUL 20-120 mg/day). Monte Carlo simulations with 1000 repetitions were used to
perform probabilistic sensitivity analyses (PSA) to examine uncertainty of the es-
timates used in the model. Outcomes from the model were expressed as cost per
quality adjusted life-year (QALY). RESULTS: In the base-case model DUL cost less
and was more effective than PRE (incremental cost -$187, incremental effective-
ness 0.011 QALYs). Results from the real-world sensitivity analyses indicated that
DUL was $16,000 and $20,667 more per QALY than PRE. Cost-effectiveness accept-
ability curves showed that DUL has a higher probability of being cost-effective,
except at very lowwillingness-to-pay thresholds. CONCLUSIONS:Using a decision
tree model that incorporated both clinical trial and real-world data, DUL was a
more cost-effective option than PRE in the treatment of PDN from the perspective
of third-party payers.
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OBJECTIVES: To estimate health care costs and utilization for Medicare beneficia-
ries with type 1 or type 2 diabetes and matched control cohorts. METHODS: We
used a retrospective claims cohort analysis to assess the direct healthcare cost and
utilization of health services in 2009 for patients aged 65 to 89 enrolled in a Medi-
care Advantage plus prescription drug plan. Patients were matched 1:1 with non-
diabetes patients. All-cause health care costs for 2009were calculated as the sumof
all medical and pharmacy claims, and costs directly attributable to diabetes were
evaluated for case cohorts. RESULTS: Our analysis included 6,562 type 1 cases and
the same number of matched controls, and 194,775 type 2 cases and their matched
controls. There were no significant demographic differences between cohorts for
matched variables. Type 2 cases had significantly higher mean Deyo-Charlson Co-
morbidity Index compared to controls (2.47 versus 0.77; p.001), although all
groups had high prevalence of expensive comorbidities such as hypertension
and heart disease. Mean all-cause healthcare costs per patient per year were
significantly higher for type 1 and type 2 cases versus controls for in-patient
hospitalization, outpatient, office, ER visits, pharmacy and total health care
costs (total 2009 costs: type 1 $20,701$30,201, type 1 controls $6,537$10,441,
type 2 $10,437$18,518, type 2 controls $6,505$11,140). The mean diabetes
attributable total health care cost for type 1 and type 2 cohorts were $9,443 
$15,665 and $3,616  $9,229, respectively, per patient per year. CONCLUSIONS:
Diabetes escalates health care costs for Medicare Advantage patients in compari-
son to those without the disease regardless of comorbidities.
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OBJECTIVES: To build a flexible and comprehensive long term Type-1 diabetes
model incorporating themost up-to-date methodologies (e.g. capturing parameter
uncertainty, timeprofile of patient characteristics and including patient behaviour)
to allow a number of cost-effectiveness evaluations.METHODS: An individual pa-
tient level discrete event simulationmodel which includes all the major complica-
tions (nephropathy, neuropathy, retinopathy, CVD, PVD, hypoglycaemia, ketoaci-
dosis) and their interactions along with the treatment effects was built based on
the developed conceptual model. Patient characteristics (demographics, clinical
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